Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -27.54% is 67% above its 5-year average of -82.63%, near the high end of its 5-year range (-4136.05%–47.49%).
97.80% above its 12-month average of -1249.73%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1656.06%.
EBITDA MARGIN
-27.54%
EBITDA MARGIN AVG TTM
-1249.73%
EBITDA MARGIN AVG 3Y
-28.47%
EBITDA MARGIN AVG 5Y
-82.63%
EBITDA MARGIN AVG 10Y
-129.62%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.80%
CURRENT VS 3Y AVG
+3.28%
CURRENT VS 5Y AVG
+66.67%
CURRENT VS 10Y AVG
+78.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CytomX Therapeutics, Inc.
Market Cap
$557.41M
EBITDA Margin
-27.54%
TTM Avg
-1249.73%
3Y Avg
-28.47%
5Y Avg
-82.63%
Market Cap
$564.07M
EBITDA Margin
52.98%
TTM Avg
1.13%
3Y Avg
-15499.35%
5Y Avg
-14628.26%
Market Cap
$566.48M
EBITDA Margin
-155.10%
TTM Avg
-103.66%
3Y Avg
-79.43%
5Y Avg
-77.63%
Market Cap
$570.28M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$541.64M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$573.32M
EBITDA Margin
-970.11%
TTM Avg
-861.99%
3Y Avg
-583.02%
5Y Avg
-735.09%
Market Cap
$530.79M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $557.41M | -27.54% | -1249.73% | -28.47% | -82.63% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $564.07M | 52.98% | 1.13% | -15499.35% | -14628.26% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $566.48M | -155.10% | -103.66% | -79.43% | -77.63% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $570.28M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $541.64M | 1.18% | -15.78% | -775.36% | -845.24% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $573.32M | -970.11% | -861.99% | -583.02% | -735.09% |
| Immix Biopharma, Inc. (IMMX)vs › | $534.23M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $530.79M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.05M | -3.28% | -4.19% | -6.19% | -9.77% |
Gross Margin
98.6%
EBITDA Margin
-27.5%
Operating Margin
-29.4%
Net Margin
-435.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1656.06% |
| 2026-03-31 | -189.33% |
| 2025-12-31 | -4136.05% |
| 2025-09-30 | -262.18% |
| 2025-06-30 | -5.03% |
| 2025-03-31 | 45.18% |
| 2024-12-31 | 47.49% |
| 2024-09-30 | 13.58% |
| 2024-06-30 | -31.83% |
| 2024-03-31 | 29.24% |
| 2023-12-31 | -0.45% |
| 2023-09-30 | 47.45% |
| 2023-06-30 | -7.35% |
| 2023-03-31 | -17.69% |
| 2022-12-31 | -44.23% |
| 2022-09-30 | -253.21% |
| 2022-06-30 | -229.08% |
| 2022-03-31 | -348.01% |
| 2021-12-31 | -125.84% |
| 2021-09-30 | -124.87% |
| 2021-06-30 | -113.75% |
| 2021-03-31 | -93.63% |
| 2020-12-31 | -86.22% |
| 2020-09-30 | -80.07% |
| 2020-06-30 | -93.42% |
| 2020-03-31 | -4.35% |
| 2019-12-31 | -444.15% |
| 2019-09-30 | -233.77% |
| 2019-06-30 | -339.13% |
| 2019-03-31 | -53.97% |
| 2018-12-31 | -220.65% |
| 2018-09-30 | -181.21% |
| 2018-06-30 | -59.96% |
| 2018-03-31 | -107.29% |
| 2017-12-31 | -3.11% |
| 2017-09-30 | -43.69% |
| 2017-06-30 | -285.69% |
| 2017-03-31 | -70.53% |
| 2016-12-31 | -219.07% |
| 2016-09-30 | -419.02% |
| 2016-06-30 | -446.44% |
| 2016-03-31 | -711.97% |
| 2015-12-31 | -563.13% |
| 2015-09-30 | -565.34% |
| 2015-06-30 | -256.49% |
| 2015-03-31 | -264.06% |
| 2014-12-31 | -238.47% |
| 2014-09-30 | -170.65% |
| 2014-06-30 | -691.29% |
| 2014-03-31 | -2625.51% |
